Aemcolo for Noninvasive Escheria coli Infection

News
Article

Aemcolo Logo

Aemcolo (rifamycin, Cosmo Pharmaceuticals)

Indications: treatment of travelers’ diarrhea caused by noninvasive strains of Escherichia coli in adults.

Dosage: Two 388mg tablets taken orally, twice daily for three days.

Contraindications: known hypersensitivity to rifamycin, any of the other rifamycin class antimicrobial agents (e.g. rifaximin), or any of the components in AEMCOLO

Click here for more prescribing information

Recent Videos
Related Content
FDA Approves Omalizumab-Igec as First Interchangeable Biosimilar to Xolair

FDA Approves Omalizumab-Igec as First Interchangeable Biosimilar to Xolair

Ashley Gallagher
March 7th 2025
Article

Omalizumab-igec is approved to treat moderate to severe persistent asthma in patients 6 years and older whose symptoms are not well controlled with inhaled corticosteroids.

Over the Counter podcast

Episode 8: Stay in Sync with Innovations in Medication Decision Support

Drug Topics staff
August 6th 2020
Podcast

Episode 8 of Over the Counter discusses the new and exciting modernizations in the medication decision support space.

FDA Approves neffy for Treatmet of Type 1 Allergic Reactions, Anaphylaxis

FDA Approves neffy for Treatmet of Type 1 Allergic Reactions, Anaphylaxis

Ashley Gallagher
March 6th 2025
Article

The approval is the first significant innovation for the delivery of epinephrine for this population in more than 35 years, according to the company news release.

FDA Approves Denosumab-Bmwo as Biosimilar to Prolia, Xgeva

FDA Approves Denosumab-Bmwo as Biosimilar to Prolia, Xgeva

Ashley Gallagher
March 4th 2025
Article

Denosumab-Bmwo is approved for all indications of the respective reference products, including osteoporosis and high-risk of fracture due to chemotherapy.

Depemokimab Demonstrates Significant Improvements in Rhinosinusitis with Nasal Polyps

Depemokimab Demonstrates Significant Improvements in Rhinosinusitis with Nasal Polyps

Brian Nowosielski
March 3rd 2025
Article

GSK announced its ANCHOR-1 and ANCHOR-2 phase 3 trial results for depemokimab’s efficacy and safety in treating patients with chronic rhinosinusitis with nasal polyps.

FDA Approves House Dust Mite Allergy Therapy For Use in Young Children

FDA Approves House Dust Mite Allergy Therapy For Use in Young Children

Ashley Gallagher
February 28th 2025
Article

The expanded indication now includes patients aged 5 through 11 years in addition to those aged 12 through 65 years.

© 2025 MJH Life Sciences

All rights reserved.